A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responsesKenneth A Lichtenstein
Division of Infectious Diseases, Department of Medicine, National Jewish Health, Denver, CO, USA
Antivir Ther 17:1301-9. 2012
..Chronic inflammation from persistent immune activation could contribute to this poor response, resulting in HIV-1 disease progression and the development of some non-HIV-1 comorbidities...
- Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study
Kenneth A Lichtenstein
National Jewish Medical and Research Center, Denver, Colorado 80206, USA
Clin Infect Dis 51:435-47. 2010
..We investigated the association of low CD4(+) T lymphocyte cell count with incident CVD in a cohort of outpatients treated in 10 HIV specialty clinics in the United States...
Antiretroviral treatment interruptions and risk of non-opportunistic diseasesKenneth A Lichtenstein
National Jewish Health, 1400 Jackson Street, G 316, Denver, CO 80206, USA
Curr HIV/AIDS Rep 6:77-82. 2009
..Structured treatment interruptions should be avoided in the management of HIV-infected individuals...
- Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency
Kenneth A Lichtenstein
University of Colorado Health Sciences Center, Denver, CO, USA
J Acquir Immune Defic Syndr 47:27-35. 2008
..US guidelines recommend deferring initiation of highly active antiretroviral therapy (HAART) for most patients with CD4 counts >350 cells/mm in part because of concerns about antiretroviral toxicity...
- Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort
Kenneth A Lichtenstein
Rose Medical Center, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262, USA
Clin Infect Dis 40:148-57. 2005
..We sought to identify factors associated with the clinical diagnosis of symmetrical peripheral neuropathy (SPN) during the era of highly active antiretroviral therapy (HAART) in a retrospective, longitudinal cohort analysis...
- Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients
Kenneth A Lichtenstein
Rose Medical Center, Unviersity of Colorado Health Sciences Center, Denver, Colorado 80220, USA
J Acquir Immune Defic Syndr 32:48-56. 2003
..Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy...
- Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients
Kenneth A Lichtenstein
National Jewish Health, Denver, CO, USA
Prev Chronic Dis 10:E10. 2013
..We investigated physicians' compliance with NCEP guidelines to reduce cardiovascular disease (CVD) risk in a population infected with HIV...
- The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study
Frank J Palella
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Ann Intern Med 151:73-84. 2009
..HIV-1 genotypic and phenotypic susceptibility testing (GPT) optimizes antiretroviral selection, but its effect on survival is unknown...
- Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006
Benjamin Young
Rocky Mountain CARES DIDC, Denver, Colorado 80220, USA
Clin Infect Dis 52:1061-8. 2011
..Among persons with HIV infection, low bone mineral density is common and has raised concerns about increased risk of fracture...
- Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection
Jennifer J Kiser
Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Pharmacotherapy 26:511-4. 2006
....
- Redefining lipodystrophy syndrome: risks and impact on clinical decision making
Kenneth A Lichtenstein
University of Colorado Infectious Disease Group Practice, Denver, 80262, USA
J Acquir Immune Defic Syndr 39:395-400. 2005
....
- Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome
Lisa A Kosmiski
Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, Denver, CO 80262, USA
Metabolism 52:620-5. 2003
..The increase in TEE appears to be due to increases in REE. The pathogenesis of elevated EE in HIV lipodystrophy and other forms of lipodystrophy remains to be determined...
- The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities
Peter L Anderson
University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Clin Infect Dis 38:743-53. 2004
..Such research should include comparisons of NRTI phosphorylation according to sex and cellular activation state (i.e., elevated vs. low)...
